Teladoc Health stock falls 3.46 percent after weak Q2 revenue

Published on 09/24/2026 at 10:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Teladoc Health stock stood at USD 6.13 on September 23, 2026, 38.02 percent below its 52-week high. Q2 revenue reached USD 606.9 million and Integrated Care posted a 16.5 percent margin.

TDOC, US87918A1051, Illustration mit AI erstellt.

Teladoc Health stock (ISIN US87918A1051) fell 3.46 percent to USD 6.13 at the official close on the NYSE on September 23, 2026. The latest quarterly figures show a split picture, with weaker consolidated revenue but stronger profitability in Integrated Care.

Revenue falls in Q2

Teladoc Health generated USD 606.9 million in Q2 2026 revenue, a 4 percent year-over-year decline, according to Yahoo Finance. The figure also fell short of the USD 615.4 million consensus cited in the same report, leaving revenue as the central pressure point.

Teladoc reported a Q2 diluted loss of USD 0.21 per share, while the consensus estimate stood at a loss of USD 0.24, according to the company earnings data. The 3-cent improvement against expectations contrasts with the revenue miss and helps explain why the earnings picture is not uniformly negative.

Integrated Care carries earnings

Integrated Care delivered USD 394.3 million in Q2 revenue and USD 65.2 million in adjusted EBITDA, with a 16.5 percent margin, according to Zacks. That segment is becoming the earnings anchor as BetterHelp works through a transition from cash-pay services toward insurance coverage.

The contrast matters because the company combines virtual primary care, chronic-care programs, mental-health services and specialist support. Integrated Care therefore offers a measurable counterweight to pressure in BetterHelp, while the consolidated revenue decline shows that the transition still affects the group total.

Stock remains below yearly high

At USD 6.13 on September 23, 2026, Teladoc Health traded inside a 52-week range of USD 4.40 to USD 9.89. The closing price was 38.02 percent below the yearly high, while the market capitalization stood at USD 1,113,722,920 on the same date.

The investor calculation is straightforward: the stock price reflects a business still reporting a quarterly loss, but the Q2 comparison also shows a segment with a 16.5 percent adjusted EBITDA margin. Revenue stabilization and execution in insurance remain the numerical tests for the next update.